Discussion
In this report, we have described the clinical outcome of PMD after UCBT in a young boy. There was initial stabilization followed by improvement in neurological symptoms. There are mainly two clinical phenotypes of PMD - conatal and classic. Conatal PMD refers to the most severe form of the disease, with symptoms appearing at birth or within few weeks of life. These patients have severe stridor, seizures, hypotonia which later on develops to spasticity, dystonia and inability to walk or talk. The other form, classic PMD, is milder and presents with nystagmus at 2 to 6 months of age (1). Our patient although presented at 18-months of age but had severe symptoms -hypotonia, seizures and had developmental delay at presentation. MRI brain of PMD patients showed diffuse pattern of hypomyelination. Affected white matter regions include the cerebral hemispheres, cerebellum, and brainstem. Thinning of the corpus callosum and atrophy of the cerebral hemispheres is sometimes seen. Since this is a rare disease, formal natural history studies are lacking.
There are no curative treatments available. Various researchers have used different strategies. Although UCBT has been used to treat many inherited metabolic disorders but only recently, it has been investigated in PMD patients. Wishnew et al. demonstrated neurological improvement in two patients aged 9 months and 29 months respectively who underwent UCBT for PMD in their centre. With 7-year and 1-year follow-up, they showed stabilization of disease with significant gains in cognitive skills and modest gains in motor development along with stable engraftment. MRI results also suggested interval myelination in these patients (4). Our patient is now more than 24-months post UCBT and has shown overall good improvement in all domain of development. Child can walk, speak, play and follow instructions. No further seizures were recorded post-transplant. Post-transplant MRI in our case has not shown much change in myelination.
Gupta et al. reported a 1-year open-label phase 1 study undertaken to evaluate safety and to detect evidence of myelin formation after human central nervous system stem cells (HuCNS-SC) transplantation. Allogeneic HuCNS-SCs were surgically implanted into the frontal lobe white matter in four male subjects with an early-onset severe form of PMD. Modest gains in neurological function were observed in three of the four subjects (5). Further follow up of these 4 children for another 4-years has been reported recently. At year 2, all subjects exhibited diffusion MRI changes at the implantation sites as well as in more distant brain regions. There were persistent, increased signal changes in the three patients who were studied up to year 5. Two of four subjects developed donor-specific HLA alloantibodies, demonstrating that neural stem cells can elicit an immune response when injected into the CNS (6). Osorio et al. reviewed the use of various stem cells in the treatment of PMD without any breakthrough success (7). Our case has achieved better developmental milestones as compared to all the reported cases in literature; 2 post UCBT and 4 post HuCNS-SC who had minimal to modest improvement. In conclusion, UCBT lead to disease stabilisation and improvement in development of the child with PMD. Long-term follow up of our case is needed.
Disclosure – All authors have nothing to declare